Palivizumab (r)
A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease
Palivizumab
Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion
Palivizumab bei viralen Atemwegsinfekten
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry